Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

29-05-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: Perioperative durvalumab for locally advanced RCC

Moshe Ornstein reports on a phase 1b trial of perioperative durvalumab alone or alongside tremelimumab for the treatment of locally advanced renal cell carcinoma (5:17).

This independent video interview was supported by an educational grant from Pfizer and Merck KGaA

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Read transcript

Related content

21-02-2020 | ASCO GU 2020 | Conference coverage | News

Durvalumab–savolitinib duo has potential in metastatic papillary renal cell carcinoma

15-10-2019 | Renal cell carcinoma | Conference coverage | News

TITAN-RCC showcases tailored immunotherapy approach

07-10-2019 | Renal cell carcinoma | Video | Article

Researcher comment: A novel CXCR4 inhibitor for RCC and a novel immunotherapy endpoint
  • » This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.
Image Credits